Poly(2-ethyl-2-oxazoline) Lipids Enhance LNP mRNA Delivery
2026-07-14
The referenced study introduces poly(2-ethyl-2-oxazoline) (PEtOx)-lipids as substitutes for conventional PEG-lipids in lipid nanoparticle (LNP) formulations, addressing the 'PEG dilemma' of rising anti-PEG antibodies. By systematically varying PEtOx polymer length, the researchers identified formulations with superior mRNA delivery, immunoevasion, and transfection efficiency, offering a promising foundation for future gene regulation and mRNA delivery technologies.
Cambinol: Unlocking SIRT1/2 Inhibition for Translational Imp
2026-07-13
This thought-leadership article explores how SIRT1/2 Inhibitor IV (cambinol) is redefining the toolkit for translational researchers bridging metabolic-epigenetic mechanisms in cancer and CNS injury models. Integrating new mechanistic insights on SIRT1-regulated Ran lactylation in astrocyte polarization, the piece provides protocol guidance, competitive context, and a strategic outlook for next-generation research.
ERK1/2 Inhibition: Bridging Oncology and Liver Disease with
2026-07-13
This article explores how GDC-0994, a potent ERK1/2 inhibitor from APExBIO, is transforming translational research at the intersection of cancer and hepatic disease. Beyond its established antineoplastic applications, new mechanistic insights reveal the centrality of ERK1/2 signaling in cholestatic liver injury, linking oncology and hepatology through shared molecular pathways. We discuss the biological rationale, experimental validation, competitive landscape, key protocol parameters, and future outlook for leveraging GDC-0994 in multidomain research.
Polybrene (Hexadimethrine Bromide): Optimizing Viral Gene De
2026-07-12
Polybrene (Hexadimethrine Bromide) dramatically increases viral gene transduction and DNA transfection efficiency, particularly in hard-to-transfect cell lines. Expert-backed workflows and troubleshooting tips ensure reproducibility and robust data, establishing APExBIO’s formulation as the gold standard for advanced biomedical research.
Ionizing Radiation Alters Neuronal Differentiation via PI3K-
2026-07-10
This study demonstrates that ionizing radiation (IR) triggers atypical neuronal differentiation in C17.2 mouse neural stem-like cells, mediated by PI3K-STAT3-mGluR1 and PI3K-p53 signaling pathways. The findings highlight how IR not only affects neural stem cell survival but can also disrupt neuronal function, with implications for understanding the side effects of radiotherapy on brain tissues.
Kinase Regulation of ECM Internalisation Drives Cancer Cell
2026-07-09
Martinez et al. introduce a high-content screening approach to identify kinase regulators of extracellular matrix (ECM) internalisation in invasive carcinoma cells. Their findings implicate the α2β1 integrin–p38 MAPK axis in mediating ECM uptake and migration, revealing new mechanistic insights into tumor invasiveness and potential therapeutic targets.
Deracoxib and Piroxicam in Canine Osteosarcoma: Cytotoxicity
2026-07-09
This study systematically investigated the cytotoxic effects of deracoxib and piroxicam on canine osteosarcoma cell lines, revealing differential potency and lack of apoptosis induction at tested concentrations. The findings refine our understanding of NSAID mechanisms in sarcoma models and inform the design of integrin-targeted research tools.
iPSC-Based Drug Screening for Ultrarare Disease Trial Select
2026-07-08
This study establishes a patient-specific induced pluripotent stem cell (iPSC) platform to prescreen drug responses for individuals with ultrarare pathogenic mutations, exemplified by a Leigh-like syndrome patient with novel ECHS1 variants. The approach demonstrated the feasibility of tailoring clinical trial selection to improve therapeutic precision and reduce risk in rare disease contexts.
Zosuquidar (LY335979) 3HCl: Benchmarking P-gp Inhibition in
2026-07-08
Zosuquidar (LY335979) 3HCl is a potent, selective P-glycoprotein (P-gp) inhibitor that reverses multidrug resistance (MDR) in cancer by restoring sensitivity to chemotherapy. At low micromolar concentrations, it blocks P-gp-mediated efflux and has demonstrated efficacy in both preclinical and clinical models. APExBIO supplies this compound for research, enabling advanced translational workflows.
Berberine Hydrochloride: Gut-Bone Axis, Energy Metabolism &
2026-07-07
Explore the multifaceted biological activities of Berberine hydrochloride, with a deep dive into gut-bone axis regulation, metabolic signaling, and advanced translational assay design. This article offers a unique perspective for researchers seeking rigorous, mechanistic insights.
Apicidin Disrupts Oocyte Maturation via HDAC Inhibition and
2026-07-07
This study reveals that Apicidin, a naturally derived histone deacetylase inhibitor and emerging mycotoxin, impairs oocyte quality by disrupting meiotic apparatus assembly and altering histone acetylation. The findings provide novel mechanistic insights into reproductive toxicology and highlight the need for careful assessment of HDAC inhibitors in both environmental and research contexts.
Phagocytic Polyploid Giant Cancer Macrophages in Blood: Clin
2026-07-06
This study provides the first multi-institutional prospective phenotyping of circulating polyploid giant cancer macrophages (CAMLs) across diverse solid tumors. The findings reveal that CAMLs correlate strongly with disease progression and mimic metastatic niche initiation, establishing them as a clinically relevant biomarker with potential to reshape metastasis research.
Berberine Hydrochloride: Mechanisms, Evidence, and Protocols
2026-07-06
Berberine hydrochloride is a bioactive alkaloid with validated antibacterial and metabolic effects. Recent studies highlight its role in gut-bone axis modulation and insulin resistance reduction, expanding its utility beyond traditional antidiarrheal applications.
Single Dose Indometacin Sodium for Acute Postoperative Pain:
2026-07-05
A Cochrane systematic review rigorously evaluated the efficacy and safety of a single oral dose of indometacin sodium for acute postoperative pain. The findings clarify its analgesic value compared to other NSAIDs and inform optimal dosing strategies for pain management in clinical and experimental settings.
VX-702 and the Next Frontier of p38α MAPK Inhibition in Tran
2026-07-04
VX-702 exemplifies a new era of p38α MAPK inhibition by leveraging dual-action mechanisms that not only block kinase activity but also accelerate dephosphorylation, offering translational researchers an unprecedented tool for dissecting and modulating inflammatory pathways. This article bridges recent mechanistic advances with practical strategies, contextualizing VX-702 within both the competitive landscape and the evolving demands of disease model optimization.
459 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page